Halozyme Therapeutics competitorsClear all

Halozyme Therapeutics's top competitors include Partner Therapeutics, Verastem Oncology, Rakuten Medical, Blueprint Medicines and Karyopharm Therapeutics.
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background
Halozyme Therapeutics
Halozyme Therapeutics
Halozyme Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing cancer therapies that target the tumor microenvironment.
Partner Therapeutics
Partner Therapeutics
Partner Therapeutics is developing and commercializing cancer medicines and combination therapies.
Verastem Oncology
Verastem Oncology
Verastem Oncology is a biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer.
Rakuten Medical
Rakuten Medical
Rakuten Medical (formerly Rakuten Aspyrian) is a clinical stage biotechnology company developing tumor-targeted precision therapies.
Blueprint Medicines
Blueprint Medicines
Blueprint Medicines discovers and develops highly selective kinase inhibitors for patients with genomically defined cancers.
Karyopharm Therapeutics
Karyopharm Therapeutics
Karyopharm Therapeutics is a clinical-stage pharmaceutical company developing drugs for the treatment of cancer and other major diseases.
Founding Date
Founding Date
1998
Founding Date
2017
Founding Date
2010
Founding Date
2013
Founding Date
2011
Founding Date
2008
Type
Type
Public
Type
Private
Type
Public
Type
Private
Type
Public
Type
Subsidiary
Tags
Locations
Locations
San Diego, US HQ
Locations
Lexington, US HQ
Boston, US
Lynnwood, US
Locations
Needham, US HQ
Walsrode, DE
Locations
San Diego, US HQ
Sinn, DE
Setagaya City, JP
Amsterdam, NL
Ecublens, CH
see more
Locations
Cambridge, US HQ
Zug, CH
Cambridge, US
Locations
Newton, US HQ
München, DE
Employees
Employees
1363% increase
Employees
1733% decrease
Employees
4864% decrease
Employees
1751% increase
Employees
38376% increase
Employees
4772% decrease
Valuation ($)
Valuation ($)
5.5 b
Valuation ($)
N/A
Valuation ($)
438.4 m
Valuation ($)
N/A
Valuation ($)
6 b
Valuation ($)
N/A
Twitter followers
Twitter followers
265
Twitter followers
134
Twitter followers
2.5 k
Twitter followers
N/A
Twitter followers
2.3 k
Twitter followers
N/A
Number of tweets (last 30 days)
Number of tweets (last 30 days)
15
Number of tweets (last 30 days)
3
Number of tweets (last 30 days)
9
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
14
Number of tweets (last 30 days)
N/A
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
1.3
Average likes per tweet (last 30 days)
2.7
Average likes per tweet (last 30 days)
12.3
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
4.9
Average likes per tweet (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
80%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
92.86%
Percentage of tweets with engagement (last 30 days)
N/A
Alexa Website Rank
Alexa Website Rank
242121
Alexa Website Rank
462492
Alexa Website Rank
272934
Alexa Website Rank
266515
Alexa Website Rank
311593
Alexa Website Rank
240977
Employee Rating
Employee Rating
3.4
Employee Rating
4.2
Employee Rating
4.3
Employee Rating
2.7
Employee Rating
3.7
Employee Rating
3.6

Financial

Revenue (est.)
Revenue (est.)
$267.6m (FY, 2020)
Revenue (est.)
N/A
Revenue (est.)
$88.5m (FY, 2020)
Revenue (est.)
N/A
Revenue (est.)
$793.7m (FY, 2020)
Revenue (est.)
$108.1m (FY, 2020)
Cost of goods
Cost of goods
$43.4m (FY, 2020)
Cost of goods
N/A
Cost of goods
$33.7m (FY, 2020)
Cost of goods
N/A
Cost of goods
$425k (FY, 2020)
Cost of goods
N/A
Gross profit
Gross profit
$224.2m (FY, 2020)
Gross profit
N/A
Gross profit
$54.8m (FY, 2020)
Gross profit
N/A
Gross profit
$793.3m (FY, 2020)
Gross profit
N/A
Net income
Net income
$129.1m (FY, 2020)
Net income
N/A
Net income
($67.7m) (FY, 2020)
Net income
N/A
Net income
$313.9m (FY, 2020)
Net income
($196.3m) (FY, 2020)

Operating

Phase II Trials Products
Phase II Trials Products
1 (FY, 2020)
Phase II Trials Products
N/A
Phase II Trials Products
4 (FY, 2020)
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A

Funding

Latest funding round
Latest funding round
N/A
Latest funding round
$ 60m (over 3 years ago)
Latest funding round
N/A
Latest funding round
$ 100m (about 2 years ago)
Latest funding round
N/A
Latest funding round
N/A
Total funding raised
Total funding raised
$ 45m
Total funding raised
$ 60m
Total funding raised
$ 170m
Total funding raised
$ 451.9m
Total funding raised
$ 115m
Total funding raised
$ 248.7m
For sources of this data, please see the company profile

View company profiles

Partner Therapeutics
HQ
Lexington, US
Employees
173↓ 3% decrease

Partner Therapeutics is developing and commercializing cancer medicines and combination therapies.

View company
Verastem Oncology
HQ
Needham, US
Employees
48

Verastem Oncology is a biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer.

View company
Rakuten Medical
HQ
San Diego, US
Employees
175↑ 1% increase

Rakuten Medical (formerly Rakuten Aspyrian) is a clinical stage biotechnology company developing tumor-targeted precision therapies.

View company
Blueprint Medicines
HQ
Cambridge, US
Employees
383

Blueprint Medicines discovers and develops highly selective kinase inhibitors for patients with genomically defined cancers.

View company